Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

Sho, T; Suda, G; Ogawa, K; Kimura, M; Kubo, A; Tokuchi, Y; Kitagataya, T; Maehara, O; Ohnishi, S; Shigesawa, T; Nakamura, A; Yamada, R; Ohara, M; Kawagishi, N; Natsuizaka, M; Nakai, M; Morikawa, K; Furuya, K; Baba, M; Yamamoto, Y; Suzuki, K; Izumi, T; Meguro, T; Terashita, K; Ito, J; Miyagishima, T; Sakamoto, N

Suda, G (corresponding author), Hokkaido Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.

HEPATOLOGY RESEARCH, 2021; 51 (9): 979

Abstract

Aim A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular car......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索